Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Monoclonal TCL1A Primary Antibody for IHC (fro), IHC (p) - ABIN1109210
Rodig, Vergilio, Shahsafaei, Dorfman: Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. in The American journal of surgical pathology 2007
Show all 7 references for ABIN1109210
Human Monoclonal TCL1A Primary Antibody for FACS - ABIN2663891
Laine, Künstle, Obata, Sha, Noguchi: The protooncogene TCL1 is an Akt kinase coactivator. in Molecular cell 2000
Show all 7 references for ABIN2663891
Human Monoclonal TCL1A Primary Antibody for FACS - ABIN2658007
Noguchi, Ropars, Roumestand, Suizu: Proto-oncogene TCL1: more than just a coactivator for Akt. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007
Show all 7 references for ABIN2658007
Human Polyclonal TCL1A Primary Antibody for WB - ABIN1944776
Virgilio, Narducci, Isobe, Billips, Cooper, Croce, Russo: Identification of the TCL1 gene involved in T-cell malignancies. in Proceedings of the National Academy of Sciences of the United States of America 1995
Show all 4 references for ABIN1944776
Mouse (Murine) Polyclonal TCL1A Primary Antibody for ELISA, WB - ABIN190822
Shen, Ferguson, Renard, Hoyer, Kim, Hao, Alt, Roeder, Morse, Teitell: Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. in Blood 2006
Human Polyclonal TCL1A Primary Antibody for WB - ABIN2787835
Herling, Patel, Teitell, Konopleva, Ravandi, Kobayashi, Jones: High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. in Blood 2007
results indicate that decreased Cav-1 (show CAV1 Antibodies) in Emu-TCL1 mice significantly delays the onset of CLL and decreases leukemic progression by inhibiting MAPK-Erk (show MAPK1 Antibodies) signaling, suggesting a role for Cav-1 (show CAV1 Antibodies) in the proliferation and progression of CLL
This review discusses the main features of the original TCL1 models and the different lines of research successively developed with particular attention to genetically compound mice and the therapeutic applications in drug development.
Tcl1 expression downregulated a distinct group of genes, including Ndp52 (show CALCOCO2 Antibodies), whose expression is very high in blastocysts but reduced in the primitive ectoderm.
Data indicate that APRIL expression accelerates the onset of TCL1-driven leukemia formation mainly through TACI (show TNFRSF13B Antibodies) activation.
These findings demonstrate cooperation of Tcl1 and the NF-kB pathway in the pathogenesis of aggressive chronic lymphocytic leukemia.
An important role of TCL1 in activating the ER stress response in support for malignant progression of chronic lymphocytic leukemia.
TCL1 and/or other genes in the TCL1 pathway are responsible for the initiation of human chronic lymphocytic leukemia.
Akt (show AKT1 Antibodies) kinase activity can be inhibited by a peptide spanning the betaA strand of the proto-oncogene TCL1
Tcl1 is a coactivator of Akt (show AKT1 Antibodies) signaling, in normal T- and B-cell development and function.
Detailed mechanism for TCL1-augmented signaling helps explain the delayed occurrence of mature T cell expansions and leukemias despite tumorigenic TCL1 dysregulation that begins in early thymocytes.
TCL1A is not only a useful biomarker for prognostic evaluation in stage II/III colorectal cancer patients.
Our results suggest that intratumoral TCL1A+ B cells are important for controlling cervical cancer development.
Our study suggests that TCL1 expression profile may have a role in the prediction of overall outcome in patient with MCL (show FH Antibodies) and call for prospective studies.
We investigated TCL1 expression at the protein level in the bone marrow of a series of 59 patients with Waldenstrom macroglobulinemia: 76% of patients expressed TCL1, which appeared to be associated with a pejorative prognostic impact.
Suggest miR (show MLXIP Antibodies)-181b as therapeutic target for chronic lymphocytic leukemia in the Emicro-TCL1 mouse model.
High TCL1A expression is associated with chronic lymphocytic leukemia.
Polymorphic genetic variations of cytochrome P450 19A1 (show CYP19A1 Antibodies) and T-cell leukemia 1A genes in the Tamil population
Peptide-based TCL1-interphase mimics were potent in steric AKT (show AKT1 Antibodies) antagonization.
demonstrated that miR (show MLXIP Antibodies)-3676 targets three consecutive 28-bp repeats within 3'UTR (show UTS2R Antibodies) of TCL1 and showed that miR (show MLXIP Antibodies)-3676 is a powerful inhibitor of TCL1
Case Report: T-cell lymphoblastic leukemia/lymphoma with t(7;14)(p15 (show CDKN2B Antibodies);q32) [TCRgamma-TCL1A translocation] confirmed by FISH.
Overexpression of the TCL1 gene in humans has been implicated in the development of mature T cell leukemia, in which chromosomal rearrangements bring the TCL1 gene in close proximity to the T-cell antigen receptor (TCR)-alpha (MIM 186880) or TCR-beta (MIM 186930) regulatory elements (summarized by Virgilio et al., 1998
T-cell leukemia/lymphoma 1A
, T-cell lymphoma-1
, T-cell leukemia/lymphoma protein 1A
, T-cell lymphoma breakpoint 1
, oncogene TCL-1
, oncogene TCL1
, protein p14 TCL1
, T-cell leukemia/lymphoma protein 1A (P14 TCL1 protein) (TCL1 oncogene) (TCL-1 protein)